BeiGene was founded in late 2010 by John V. Oyler, [11] an American entrepreneur who serves as the company's chief executive officer and chairman, [30] alongside Xiaodong Wang, a Chinese American biochemist.

2024年12月23日 · BeiGene is a global, science-driven oncology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.

Clare Fisher joined BeiGene in 2021 as Senior Vice President, Business Development and Mergers & Acquisitions (ex-China), bringing more than two decades of healthcare experience in leadership roles including corporate and business development, M&A, and strategy.

2020年7月13日 · In an eye-catching transpacific collaboration last year, Amgen poured out $2.7 billion to tap into BeiGene’s commercial and R&D expertise in China. But what if an additional equity raise diluted...

2019年11月1日 · Amgen is paying $2.7 billion for a 20.5% stake in BeiGene. The investment will put BeiGene at the heart of Amgen’s efforts to develop oncology drugs for the Chinese market.

2019年11月14日 · The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's strategy of largely using data from trials held outside...

2023年3月14日 · Now, the former junior doctor leading the medical affairs team at one of China's biggest cancer biopharmaceutical companies is growing the business into an international juggernaut. And it couldn't come at a better time for BeiGene, which received its first U.S. regulatory greenlight in 2019 for the cancer drug Brukinsa.

2020年1月3日 · The official launch of a strategic partnership with BeiGene gives Amgen “an efficient way” to gain access to China’s oncology market, analysts figure.

2019年11月1日 · Amgen will pay Chinese oncology specialist BeiGene $2.7 billion for a 21% stake in a wide-ranging collaboration that will see BeiGene commercialize three marketed cancer drugs and up to 20 in development in China.

2024年9月18日 · JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in...